Navigation Links
New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy
Date:9/24/2008

ibits the rapid firing nerve cells that cause seizures, has been developed to address the need for a new anti-epileptic agent that offers a reduction in seizure frequency combined with a favourable tolerability profile. Zebinix(TM) is currently under review by the EMEA (European Medicines Agency) for the treatment of partial-onset seizures with or without secondary generalisation in combination with other anti-epileptic drugs. A US NDA (New Drug Application) is expected later in 2008 or early 2009.

About the trials

The three phase III, multi-centre, randomised, placebo controlled trials involved more than 1,000 patients from 23 countries. Patients had a history of at least four partial seizures per month despite treatment with up to three concomitant anti-epileptic drugs.(2,3,4)

During the trials, patients were randomised to eslicarbazepine acetate or placebo and after a 2-week titration period, were assessed over a 12 week maintenance period, with continued follow-up over a one year open-label period.(2,3,4,7)

Efficacy

Over the 12 week maintenance period, Zebinix(TM) 800mg and 1200mg reduced seizure frequency by over one third, and was significantly more effective than placebo. This significant decrease in seizure frequency was sustained over the one-year open label treatment period and was consistent regardless of baseline therapy..(2,3,4) Similar positive findings were observed in the responder rate (greater-than-or-equal-to 50% decrease in seizure frequency) for Zebinix(TM) 800mg and 1200mg that ranged between 32% and 43% across all three phase III trials. (2,3,4)

Tolerability

The safety profile of Zebinix(TM) was favourable. The majority of treatment related adverse events were mild or moderate in severity and after 6 weeks, no relevant differences in the incidence of adverse events were apparent between patients treated with eslicarbazepine acetate and patients treated with placebo. In patients treated with Zebi
'/>"/>

SOURCE BIAL
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
2. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
3. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
4. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
5. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
6. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
7. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
8. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
9. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
10. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
11. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015  St. Vincent Healthcare is raising the ... following strict disinfection routines, St. Vincent Healthcare is now ... harmful germs, like Ebola, methicillin-resistant Staphylococcus aureus ... infect patients during their hospital stay. ... - http://photos.prnewswire.com/prnh/20150420/199749LOGO ...
(Date:4/21/2015)... 21, 2015  IntelliQuit™, the world,s first smartphone breathalyzer for smokers, was selected to present as ... New York City on Wednesday April 22.  ... ... ... Thirty percent (30%) of all cardiovascular disease is caused ...
(Date:4/21/2015)...  Navitas has launched Aviator, a Cloud Based Platform ... for life sciences clients. Aviator supports Regulatory, Clinical and ... flow of data across all applications and into the ... closely with Oracle to provide Argus, Life Sciences Data ... Cloud. ...
Breaking Medicine Technology:St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 2St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 3IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 2IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 3Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 2Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 3Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 4
(Date:4/21/2015)... 2015 The report “Sinusitis ... analysis on the therapeutic development for Sinusitis. ... new targets and MOAs to produce first-in-class ... is available @ http://www.rnrmarketresearch.com/sinusitis-pipeline-review-h1-2015-market-report.html . ... involved in the therapeutic development for Sinusitis ...
(Date:4/21/2015)... Information is the best weapon in the fight ... patients and their families with knowledge about living with cancer ... is the Answer" and new website . , In ... patients from diagnosis through treatment and even death. The goal, ... treatment, at home and in the examination room. , “Cancer ...
(Date:4/21/2015)... 2015 Lyft has announced the ... otolaryngologists, bringing the most advanced speech-recognition technology to ... Otolaryngologists can now experience the full benefits of ... in the industry, Lyft, which offers value-added support ... , “Lyft is very excited to be able ...
(Date:4/21/2015)... On April 8th, 2015, Choices Recovery ... the world famous Avalon Hollywood. Organized by Debbie Durkin, ... TV and film, the EcoLuxe Lounge is a premier ... ceremonies and festivals throughout the year. A gathering of ... socially conscious products and services, this daylong event is ...
(Date:4/21/2015)... Colmar, PA (PRWEB) April 21, 2015 ... Ichthyosis & Related Skin Types, Inc.® (FIRST) will publish ... ichthyosis. The campaign will run throughout the month of ... Voice. It Matters to Someone." The positioning was ... about this rare skin disorder and to help support ...
Breaking Medicine News(10 mins):Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2Health News:Lyft Expands Its Offerings to Include Dragon® Medical Practice Edition 2 for Otolaryngologists. 2Health News:Hollywood's Santana Dempsey and Choices Recovery South Bend Examine Victory over Personal Struggles 2Health News:May is Ichthyosis Awareness Month. Use Your Voice. 2
... Insured or not, patients forgo medical needs twice as ... 4 (HealthDay News) -- Unmanageable health-care costs are forcing ... United States to go without the medical attention they ... study indicates that Hispanic and African-American cancer survivors are ...
... Annual Scientific Meeting in Chicago, IL, on April 25-30, ... meeting of urologic professionals in the world, and is ... from around the world. This year, more than 2,000 ... will showcase their products and services in the Science ...
... Feb. 4 Franklin & Seidelmann,( http://www.franklin-seidelmann.com ... penetration into the hospital sector with the,addition of three ... , -- Barnes-Kasson Hospital, Susquehanna, PA, ... KY, -- Syringa General Hospital, Grangeville, ...
... world seeks new ways to prevent and treat chronic diseases ... to be conducted on the benefits of certain foods in ... are often cited as being high in antioxidants, which have ... cells within the body, reducing the risk of cancer and ...
... Excellent Source of Omega-3s EPA/DHA and 170% Daily Requirement of ... SMBL ) today announced that it will launch ... and Albany metro areas and New England during the first ... varieties and currently sold in Florida and Georgia, tastes rich ...
... chief architect of BurrellesLuce 2.0, will be the featured speaker at ... Society of America. , ... Livingston, NJ (PRWEB) February 4, 2009 -- ... 2.0 , will be the featured speaker at the Feb. 11th ...
Cached Medicine News:Health News:Cancer Survivors Say Costs Keep Them From Care 2Health News:Cancer Survivors Say Costs Keep Them From Care 3Health News:Cancer Survivors Say Costs Keep Them From Care 4Health News:Franklin & Seidelmann Expands into Critical Access Hospital Market Provides 24 x 7 Teleradiology Service for Three New Clients 2Health News:Franklin & Seidelmann Expands into Critical Access Hospital Market Provides 24 x 7 Teleradiology Service for Three New Clients 3Health News:Dry beans inhibit development of mammary cancer 2Health News:Smart Balance to Bring Milk with More Taste and Less Fat to New York City and Albany Metro Areas and New England 2Health News:Smart Balance to Bring Milk with More Taste and Less Fat to New York City and Albany Metro Areas and New England 3Health News:BurrellesLuce IT Expert to Explore Web 3.0's Potential PR Impact At February Luncheon Meeting of Westchester/Fairfield PRSA 2Health News:BurrellesLuce IT Expert to Explore Web 3.0's Potential PR Impact At February Luncheon Meeting of Westchester/Fairfield PRSA 3
... optical collection, inspired by the ... Mademoiselle's heart, from the interlinked ... effect. Combining the purity of ... Strass and other light reflections, ...
... and sunwear, inspired by modern ... style, with long lasting wearability. ... collection include sophistication, elegance and ... clean modern shapes, classic styling ...
... frame mounting technology has redefined rimless collections ... taper at the end of each frame ... of the bushing that mounts within the ... a secure fit is created that far ...
... The new GUCCI DONNA eyewear collection ... house,incorporating, with a vintage yet contemporary feel, ... leader., The new GUCCI UOMO optical and ... is,presented in classic lines with cutting-edge design ...
Medicine Products: